iii Scientists awarded UKRI-MRC-COVID-19 grant
Published: 16 November 2020
Institute of Infection, Immunity and Inflammation scientists have been awarded a grant from UKRI-MRC to address important and as-yet unanswered questions about the role of myeloid cells in severe COVID-19.
Institute of Infection, Immunity and Inflammation scientists have been awarded a grant from UKRI-MRC to study COVID-19.
RACE scientists Dr Mariola Kurowska-Stolarska (PI), Dr Thomas Otto, Professor Iain B. McInnes, Professor Carl Goodyear, and Dr Megan MacLeod, Dr Christopher Boutell (Centre for Virus Research), Dr Kristina Kirschner (Beatson Institute for Cancer Research) and Dr Charles McSharry (Immunobiology Centre) will work in collaboration with Dr Stefano Alivernini and Professor Elisa Gremese from COVID-19 Academic Hospital FPG-IRCCS (Rome Italy).
Together they will study 'Innate immune determinants of severity and resolution in a longitudinal study of COVID-19' to address important and as-yet unanswered questions about the role of myeloid cells in severe COVID-19.
These include:
- Can we identify characteristics of myeloid cells at an early stage of SARS-CoV-2 infection that might help predict the clinical course of disease?
- What allows myeloid cells to escape the homeostatic regulation that would normally attenuate pathology?
- Can the regulatory mechanisms be reinstated?
- Do myeloid cells retain their aberrant activated state (epigenetics) and contribute to long-term post-COVID-19 symptoms (long-COVID-19)?
First published: 16 November 2020